Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) is a pioneering commercial-stage biopharmaceutical company that specializes in the discovery, creation, and delivery of transformative medicines for patients suffering from genetic diseases and cancers with clear genetic drivers. Established in 2015, the company is headquartered in Palo Alto, California. BridgeBio's mission is to address significant unmet medical needs through genetic medicine by leveraging a comprehensive pipeline of development programs that span from early-stage scientific research to late-stage clinical trials.
The company's core focus areas include Mendelian diseases, Genetic Dermatology, Oncology, and Gene Therapy. BridgeBio’s innovative approach involves systematically mapping the genetic disease landscape to identify promising therapeutic assets. Their proprietary platform and management expertise are harnessed to accelerate the development of these early-stage assets into clinically impactful treatments.
BridgeBio’s robust pipeline boasts several notable programs:
- Acoramidis (AG10): Aiming to treat transthyretin amyloid cardiomyopathy (ATTR-CM), this next-generation, orally-administered TTR stabilizer has shown positive results in the Phase 3 ATTRibute-CM trial. The New Drug Application (NDA) for acoramidis has been accepted by the FDA, with a target decision date set for November 29, 2024.
- Infigratinib: Targeting achondroplasia and hypochondroplasia, this FGFR1-3 inhibitor aims to address skeletal dysplasias. The PROPEL 2 Phase 2 trial has demonstrated significant and sustained increases in growth velocity.
- BBP-418: Designed for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), this glycosylation substrate is under Phase 3 trials, with the potential for accelerated approval based on recent interactions with the FDA.
BridgeBio's track record includes successful capital raises, strategic partnerships, and a series of public offerings that have strengthened its financial positioning. The company recently completed a $200 million private financing for its oncology subsidiary, BridgeBio Oncology Therapeutics, to accelerate the development of its precision oncology pipeline.
Key recent developments include:
- The initiation of a comprehensive equity grants program to attract top talent in the biopharmaceutical industry.
- Positive results from multiple clinical trials, including significant improvements in health-related quality of life measures for patients with ATTR-CM treated with acoramidis.
- Ongoing collaborations with global pharmaceutical leaders like Bayer for the commercial development and distribution of key assets in international markets.
BridgeBio remains committed to advancing genetic medicine and delivering groundbreaking therapies to improve patient lives. For more information, visit bridgebio.com and follow them on LinkedIn and Twitter.
Rhea-AI Summary
BridgeBio Pharma, Inc. (BBIO) presents positive results from a CMR imaging substudy of ATTRibute-CM Phase 3 trial of acoramidis in ATTR-CM, showing potential cardiac structural and functional improvement with acoramidis treatment. The data support near-complete TTR stabilization with acoramidis leading to cardiac remodeling and functional recovery. Acoramidis was well-tolerated with no safety concerns. BridgeBio's NDA for acoramidis has been accepted by the FDA and MAA by the EMA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
BridgeBio Pharma, Inc. approved equity grants for 16 new employees totaling 71,146 shares of common stock. The grants vest over time and were made under the Amended and Restated 2019 Inducement Equity Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
-
Rhea-AI Summary
BridgeBio Pharma, Inc. announces a public offering of 8,620,690 shares of common stock at $29.00 per share, expecting gross proceeds of approximately $250.0 million. The offering includes an option for underwriters to purchase additional shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
Rhea-AI Summary
BridgeBio Pharma, Inc. announces a $250 million public offering of common stock, with an option for additional $37.5 million, managed by J.P. Morgan, Cantor Fitzgerald & Co., and Mizuho. The offering is subject to market conditions and regulatory approvals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.51%
Tags
-
Rhea-AI Summary
BridgeBio grants Bayer exclusive license to commercialize acoramidis for ATTR-CM in Europe, receiving up to $310 million USD, royalties in low-thirties percent, and potential sales milestones. Positive Phase 3 trial results led to FDA and EMA acceptance, with Bayer's expertise enhancing commercialization efforts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.19%
Tags
-
News
Rhea-AI Summary
BridgeBio Pharma, Inc. submits NDA for acoramidis to FDA for ATTR-CM treatment, presents positive Phase 3 trial results, secures funding, and reports financial results for Q4 and full year 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
Rhea-AI Summary
BridgeBio Pharma, Inc. and Kyowa Kirin Co., Ltd announced a partnership for the development and commercialization of infigratinib for achondroplasia, hypochondroplasia, and other skeletal dysplasias in Japan. BridgeBio will receive an upfront payment of USD 100 million and royalties on sales of infigratinib in Japan. Infigratinib is an oral small molecule designed to inhibit FGFR3 and target FGFR3-driven skeletal dysplasias, including achondroplasia and hypochondroplasia. The partnership aims to accelerate the development of infigratinib to provide treatment options for children with achondroplasia, hypochondroplasia, and other skeletal dysplasias in Japan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
-
Rhea-AI Summary
BridgeBio Pharma, Inc. granted 123,838 shares of common stock to 35 new employees as part of their compensation package. The shares will vest over time, subject to continued employment. The awards were made under the company's 2019 Inducement Equity Plan, adopted in November 2019 and subsequently amended in February and December 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
-
Rhea-AI Summary
BridgeBio Pharma, Inc. announces that the U.S. FDA has accepted the New Drug Application (NDA) for acoramidis, a drug for the treatment of ATTR-CM, with a PDUFA action date of November 29, 2024. The FDA is not planning to hold an advisory committee meeting. The European Medicines Agency has also accepted the Marketing Authorization Application, with additional global regulatory submissions planned. ATTRibute-CM study results showed positive outcomes, including an 81% absolute survival rate, low cardiovascular-related hospitalization frequency, and rapid clinical benefit.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
Rhea-AI Summary
BridgeBio Pharma, Inc. (Nasdaq: BBIO) shared positive results from the Japan Phase III trial of acoramidis in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), conducted by Alexion, AstraZeneca Rare Disease. The results showed consistency with the global BridgeBio ATTRibute-CM Phase III trial, with no mortality reported over the 30-month treatment period. Acoramidis was well-tolerated, with no safety signals of potential clinical concern identified. The findings support local regulatory submission in Japan. The data will be presented at a forthcoming medical meeting and submitted to Japan’s health authority for regulatory review. Acoramidis is an investigational, next-generation, oral, highly potent small molecule stabilizer of transthyretin (TTR), designed to achieve maximal stabilization and preserve native TTR.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
FAQ
What is the current stock price of Bridgebio Pharma (BBIO)?
The current stock price of Bridgebio Pharma (BBIO) is $36.85 as of February 21, 2025.
What is the market cap of Bridgebio Pharma (BBIO)?
The market cap of Bridgebio Pharma (BBIO) is approximately 7.0B.
What does BridgeBio Pharma, Inc. specialize in?
BridgeBio Pharma specializes in discovering, creating, and delivering transformative medicines for patients suffering from genetic diseases and cancers with clear genetic drivers.
What are the core focus areas of BridgeBio Pharma's pipeline?
The core focus areas include Mendelian diseases, Genetic Dermatology, Oncology, and Gene Therapy.
What are some key programs in BridgeBio's pipeline?
Key programs include acoramidis (AG10) for ATTR-CM, infigratinib for achondroplasia and hypochondroplasia, and BBP-418 for LGMD2I/R9.
What recent financial achievements has BridgeBio Pharma accomplished?
BridgeBio recently completed a $200 million private financing for its oncology subsidiary and has conducted multiple public offerings.
Has BridgeBio Pharma formed any significant partnerships?
Yes, BridgeBio has partnered with global pharmaceutical leaders like Bayer for the commercial development and distribution of key assets.
What recent clinical trial results has BridgeBio Pharma announced?
BridgeBio announced positive results from the Phase 3 ATTRibute-CM trial for acoramidis, showing significant improvements in health-related quality of life for patients with ATTR-CM.
When was BridgeBio Pharma founded?
BridgeBio Pharma was founded in 2015.
Where is BridgeBio Pharma headquartered?
BridgeBio Pharma is headquartered in Palo Alto, California.
What is the therapeutic approach of BridgeBio Pharma?
BridgeBio Pharma applies a systematic mapping of the genetic disease landscape to identify promising therapeutic assets and leverages its proprietary platform to develop these assets into impactful treatments.
How can I learn more about BridgeBio Pharma’s developments?
For more information, visit bridgebio.com and follow BridgeBio on LinkedIn and Twitter.
Bridgebio Pharma
Nasdaq:BBIO
BBIO Rankings
BBIO Stock Data
6.96B
150.77M
2.92%
92.29%
10.79%
Biotechnology
Pharmaceutical Preparations
United States
PALO ALTO